These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 7847423)

  • 21. Drug approval processes in Australian Paediatric Hospitals.
    Sinha YK; Craig JC; Barclay P; Taitz J; South M; Coulthard K; Pearson C; Erickson S; Brien JE
    Arch Dis Child; 2010 Sep; 95(9):739-44. PubMed ID: 20584852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of pharmacoeconomic data in formulary selection.
    Hatoum HT; Freeman RA
    Top Hosp Pharm Manage; 1994 Jan; 13(4):47-53. PubMed ID: 10130683
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Issues in formulary management: therapeutic interchange. The value, cost, and quality of therapeutic interchange.
    Mahoney CD
    Hosp Formul; 1992 Oct; 27 Suppl 2():2-3. PubMed ID: 10122035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The drug formulary decision-making process.
    Brehany J; Cohen P; Sax MJ
    Healthplan; 1999; 40(3):85-92. PubMed ID: 10538088
    [No Abstract]   [Full Text] [Related]  

  • 25. Do drug formulary policies reflect evidence of value?
    Neumann PJ; Lin PJ; Greenberg D; Berger M; Teutsch S; Mansley E; Weinstein MC; Rosen AB
    Am J Manag Care; 2006 Jan; 12(1):30-6. PubMed ID: 16402886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A survey of Pharmacy and Therapeutic committees across Canada: scope and responsibilities.
    Mittmann N; Knowles S
    Can J Clin Pharmacol; 2009; 16(1):e171-7. PubMed ID: 19242000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug formulary decision-making in two regional health authorities in British Columbia, Canada.
    Armstrong K; Mitton C; Carleton B; Shoveller J
    Health Policy; 2008 Dec; 88(2-3):308-16. PubMed ID: 18508151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of the microbiology laboratory in guiding formulary decisions.
    Stratton CW
    Hosp Formul; 1988 Aug; 23(8):654-7. PubMed ID: 10312591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Raising the bar in the formulary decision process.
    Navarro RP
    Manag Care Interface; 1999 Jul; 12(7):51, 54. PubMed ID: 10539501
    [No Abstract]   [Full Text] [Related]  

  • 30. What process does your P&T Committee use to obtain staff physicians' input regarding formulary decisions?
    Tompkins GC
    Hosp Formul; 1992 Feb; 27(2):197. PubMed ID: 10116717
    [No Abstract]   [Full Text] [Related]  

  • 31. Results of our national survey. Current formulary decision-making strategies and new factors influencing the process.
    Formulary; 1995 Aug; 30(8):462-70. PubMed ID: 10151734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Formulary system controversies in the new environment of DRGs.
    Lipman AG
    Hosp Formul; 1985 Feb; 20(2):218, 221-4, 229 passim. PubMed ID: 10311021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The strategic interaction between firms and formulary committees: effects on the prices of new drugs.
    García-Alonso MD; García-Mariñoso B
    J Health Econ; 2008 Mar; 27(2):377-404. PubMed ID: 18276026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The military health services system model for pharmacoeconomic decision making.
    Ries AJ; Potyk RP; Brier KL; Miller MR; Tornow JJ; Weber MP; Finder SF; Reeves CS
    Med Interface; 1995 May; 8(5):132-7. PubMed ID: 10142786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Managed care guidelines for the economic evaluation of pharmaceuticals.
    Langley PC; Martin RE
    Am J Manag Care; 1997 Jul; 3(7):1013-21. PubMed ID: 10173366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A survey of selective administration procedures in formulary maintenance.
    Quigley MA; Brown WM
    Hosp Pharm; 1981 Jul; 15(7):371-4, 378-80. PubMed ID: 10252001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improving pharmacy and therapeutics committee operations.
    Cohen MR; Klapp D; Miller KB; Shaffer VL; Slotfeldt M; Miller DE
    Am J Hosp Pharm; 1984 Sep; 41(9):1767-77. PubMed ID: 6496511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Operation, formulary decision-making activities of a P & T Committee in a managed care setting.
    Adams J; Richardson J
    Hosp Formul; 1991 Apr; 26(4):291-4, 300-1. PubMed ID: 10109798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Formulary evaluation of third-generation cephalosporins using decision analysis.
    Cano SB; Fujita NK
    Am J Hosp Pharm; 1988 Mar; 45(3):566-9. PubMed ID: 3285673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of health-related quality of life information in managed care formulary decision-making.
    Wu WK; Sause RB; Zacker C
    Res Social Adm Pharm; 2005 Dec; 1(4):579-98. PubMed ID: 17138497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.